Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. WGS
stocks logo

WGS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
120.52M
+26.01%
0.166
-73.92%
115.37M
+32.43%
0.057
-79.08%
126.42M
+23.11%
0.130
-74%
Estimates Revision
The market is revising Upward the revenue expectations for GeneDx Holdings Corp. (WGS) for FY2025, with the revenue forecasts being adjusted by 3.83% over the past three months. During the same period, the stock price has changed by 22.19%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-21.29%
In Past 3 Month
Stock Price
Go Up
up Image
+22.19%
In Past 3 Month
Wall Street analysts forecast WGS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for WGS is 155.24 USD with a low forecast of 118.42 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast WGS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for WGS is 155.24 USD with a low forecast of 118.42 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 161.950
sliders
Low
118.42
Averages
155.24
High
170.00
Current: 161.950
sliders
Low
118.42
Averages
155.24
High
170.00
Piper Sandler
David Westenberg
upgrade
$140 -> $160
2025-11-10
Reason
Piper Sandler
David Westenberg
Price Target
$140 -> $160
2025-11-10
upgrade
Reason
Piper Sandler analyst David Westenberg raised the firm's price target on GeneDx to $160 from $140 following quarterly results. The firm keeps an Overweight rating on the shares.
Guggenheim
Buy
upgrade
$115 -> $170
2025-10-29
Reason
Guggenheim
Price Target
$115 -> $170
2025-10-29
upgrade
Buy
Reason
Guggenheim raised the firm's price target on GeneDx to $170 from $115 and keeps a Buy rating on the shares following what the firm calls out as another quarter of whole exome and genome growth, strong average selling prices, and gross margin improvements. With "a large beat and even larger guidance raise," the firm does not believe management intended to signal a move to negative EPS despite management's comments on 2026 operating expenses, the analyst added.
Canaccord
Buy
maintain
$155 -> $160
2025-10-29
Reason
Canaccord
Price Target
$155 -> $160
2025-10-29
maintain
Buy
Reason
Canaccord raised the firm's price target on GeneDx to $160 from $155 and keeps a Buy rating on the shares. The firm said they remain bullish after another quarter of solid execution and continued profitable growth, driving increased long-term estimates. Canaccord noted GeneDx's strategy to convert existing customers to WES/WGS and ramp new indications is driving solid growth.
BTIG
Buy
maintain
$140 -> $165
2025-10-29
Reason
BTIG
Price Target
$140 -> $165
2025-10-29
maintain
Buy
Reason
BTIG raised the firm's price target on GeneDx to $165 from $140 and keeps a Buy rating on the shares. The company delivered another strong quarter, posting best-in-class 65% Y/Y growth in its core exome/genome revenue, resulting in an 11% top line beat and a beat to the bottom line, and the management raised its 2025 guidance, the analyst tells investors in a research note. In order to capitalize on penetrating at least one large new market opportunity - the pediatrician market - GeneDx has initiated a step-up in hiring/spending, the firm added.
Canaccord
initiated
$155
2025-10-20
Reason
Canaccord
Price Target
$155
2025-10-20
initiated
Reason
Canaccord initiated coverage of GeneDx with a Buy rating and $155 price target. The company has undergone a "significant" financial turnaround, driven by its shift to high-value exome and genome testing, the analyst tells investors in a research note. The firm says GeneDx's leading position in the "underpenetrated market" of newborn screening and its long-term opportunity in adult testing could support solid near- and long-term performance.
Piper Sandler
Overweight
maintain
$120 -> $140
2025-09-11
Reason
Piper Sandler
Price Target
$120 -> $140
2025-09-11
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on GeneDx to $140 from $120 and keeps an Overweight rating on the shares. The firm maintains a positive outlook on GeneDx, supported by its unique data asset, demonstrated execution, and compelling growth prospects. Piper thinks the company's ability to build markets within the evolving rare disease testing landscape, coupled with its strategic expansion into high-potential areas like the NICU and general pediatrics, creates a compelling multi-year growth story. While the firm is mindful of the execution risks involved in scaling new markets and integrating acquisitions, Piper believes GeneDx's leadership, differentiated data moat, and proactive strategy position it well. The stock has had a nice run, but the firm still likes the stock and recommends buying more on a pullback.
See All Ratings

Valuation Metrics

The current forward P/E ratio for GeneDx Holdings Corp (WGS.O) is 476.32, compared to its 5-year average forward P/E of 22.98. For a more detailed relative valuation and DCF analysis to assess GeneDx Holdings Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
22.98
Current PE
476.32
Overvalued PE
112.25
Undervalued PE
-66.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-80.72
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
342.23
Undervalued EV/EBITDA
-503.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.25
Current PS
0.00
Overvalued PS
56.87
Undervalued PS
-22.36
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 1652.99% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 1652.99% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

WGS News & Events

Events Timeline

(ET)
2025-10-28
06:53:31
GeneDx increases FY25 revenue forecast to $425M-$428M, up from $400M-$415M
select
2025-10-28
06:51:33
GeneDx Announces Q3 Adjusted EPS of 49 Cents, Exceeding Consensus Estimate of 42 Cents
select
2025-10-20 (ET)
2025-10-20
08:08:40
GeneDx Receives Breakthrough Device Designation for Whole Genome and Exome Testing
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
12-01PRnewswire
GeneDx Holdings Under Investigation for Potential Shareholder Rights Breach
  • Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers of GeneDx Holdings Corp. breached their fiduciary duties, potentially leading to shareholder losses.
  • Legal Relief Options: Long-term shareholders of GeneDx may seek corporate governance reforms, fund returns, or court-approved financial awards, aimed at enhancing company transparency and accountability.
  • Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby enhancing shareholder value and promoting more effective management.
  • Legal Fee Arrangement: The law firm will handle the case on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal expenses, reducing the financial burden of participation.
[object Object]
Preview
8.0
11-21NASDAQ.COM
"Invest in GeneDx Holdings at $65 and Achieve 18.5% Returns with Options"

  • Put Selling and Upside Potential: Selling a put option does not provide the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, which is contingent on the stock price declining significantly.

  • Counterparty Risk and Myths: The article discusses common myths about options, including counterparty risk, emphasizing that the only benefit for a put seller is the premium collected unless the stock price drops substantially.

  • Volatility and Trading History: GeneDx Holdings Corp's historical volatility is noted at 99%, and the article suggests using this information alongside fundamental analysis to evaluate the attractiveness of selling a specific put option.

  • Current Market Activity: Recent trading data shows a balanced volume of put and call options among S&P 500 components, indicating a higher than expected interest in put options compared to historical averages.

[object Object]
Preview
8.0
11-19NASDAQ.COM
Significant Options Trading on Tuesday: SEI, NET, WGS

  • CloudFlare Options Activity: CloudFlare Inc (NET) has seen a significant options volume of 24,267 contracts today, equating to 2.4 million underlying shares, which is 78.6% of its average daily trading volume over the past month. Notably, the $195 strike put option expiring on November 21, 2025, has recorded 1,936 contracts traded.

  • GeneDx Holdings Options Activity: GeneDx Holdings Corp (WGS) has reported an options volume of 4,651 contracts today, representing approximately 465,100 underlying shares, or 74.8% of its average daily trading volume. The $180 strike call option expiring on December 19, 2025, has seen particularly high activity with 2,500 contracts traded.

  • Options Trading Insights: The article provides insights into the trading history of both NET and WGS options, highlighting specific strike prices and their trading volumes.

  • Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is GeneDx Holdings Corp (WGS) stock price today?

The current price of WGS is 161.95 USD — it has increased 0.98 % in the last trading day.

arrow icon

What is GeneDx Holdings Corp (WGS)'s business?

GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.

arrow icon

What is the price predicton of WGS Stock?

Wall Street analysts forecast WGS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for WGS is 155.24 USD with a low forecast of 118.42 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is GeneDx Holdings Corp (WGS)'s revenue for the last quarter?

GeneDx Holdings Corp revenue for the last quarter amounts to 116.74M USD, increased 51.86 % YoY.

arrow icon

What is GeneDx Holdings Corp (WGS)'s earnings per share (EPS) for the last quarter?

GeneDx Holdings Corp. EPS for the last quarter amounts to -0.27 USD, decreased -12.90 % YoY.

arrow icon

What changes have occurred in the market's expectations for GeneDx Holdings Corp (WGS)'s fundamentals?

The market is revising Upward the revenue expectations for GeneDx Holdings Corp. (WGS) for FY2025, with the revenue forecasts being adjusted by 3.83% over the past three months. During the same period, the stock price has changed by 22.19%.
arrow icon

How many employees does GeneDx Holdings Corp (WGS). have?

GeneDx Holdings Corp (WGS) has 1000 emplpoyees as of December 05 2025.

arrow icon

What is GeneDx Holdings Corp (WGS) market cap?

Today WGS has the market capitalization of 4.68B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free